Advertisement

Uso della procalcitonina come marker del carcinoma midollare tiroideo

  • Luca GiovanellaEmail author
  • Pierpaolo Trimboli
L’Osservatorio
  • 23 Downloads

Using procalcitonin as a marker of medullary thyroid cancer

Summary

Here we reviewed the literature on the use of procalcitonin (PCT), a precursor of calcitonin (CT), as diagnostic marker of medullary thyroid carcinoma (MTC) in both preoperative and postsurgical setting. To date, about forty articles have been published on this topic. Some of these evaluated the reliability of PCT to detect MTC in thyroid nodule patients, and the other ones investigated the performance of PCT to identify recurrent MTC during postoperative follow-up. Based on published data, PCT measurement appears a promising and reliable serum marker for the diagnosis of MTC. The sample handling of PCT is less laborious and in specific conditions its assay could have significant impact and higher accuracy than CT. Some potential cut-offs have been reported but it would be worthwhile to establish a fixed threshold to use PCT during clinical practice.

Keywords

Medullary thyroid cancer Calcitonin Procalcitonin 

Notes

Conflitti di interesse

Nessuno.

Studi condotti su esseri umani e animali

Non applicabile.

Consenso informato

Non applicabile.

Bibliografia

  1. 1.
    Wells SA Jr, Asa SL, Dralle H et al. (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610 CrossRefGoogle Scholar
  2. 2.
    Trimboli P, Treglia G, Guidobaldi L et al. (2015) Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 82:280–285 CrossRefGoogle Scholar
  3. 3.
    Pusztaszeri MP, Bongiovanni M, Faquin WC (2014) Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol 21:26–35 CrossRefGoogle Scholar
  4. 4.
    Trimboli P, Giovanella L, Crescenzi A et al. (2014) Medullary thyroid cancer diagnosis: an appraisal. Head Neck 36:1216–1223 CrossRefGoogle Scholar
  5. 5.
    Trimboli P, Giovanella L (2015) Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med 53:1507–1514 CrossRefGoogle Scholar
  6. 6.
    Algeciras-Schimnich A, Preissner CM, Theobald JP et al. (2009) Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 94:861–868 CrossRefGoogle Scholar
  7. 7.
    Kratzsch J, Petzold A, Raue F et al. (2011) Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 57:467–474 CrossRefGoogle Scholar
  8. 8.
    Kaczka K, Mikosiński S, Fendler W et al. (2010) Can procalcitonin be useful for medullary thyroid cancer? Endokrynol Pol 61:430–436 Google Scholar
  9. 9.
    Kaczka K, Mikosiński S, Fendler W et al. (2012) Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med 21:169–178 Google Scholar
  10. 10.
    Walter MA, Meier C, Radimerski T et al. (2010) Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer 116:31–40 Google Scholar
  11. 11.
    Trimboli P, Lauretta R, Barnabei A et al. (2018) Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers 33:156–160 CrossRefGoogle Scholar
  12. 12.
    Machens A, Lorenz K, Dralle H (2014) Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab 99:2986–2994 CrossRefGoogle Scholar
  13. 13.
    Giovanella L, Verburg FA, Imperiali M et al. (2013) Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 51:1477–1481 Google Scholar
  14. 14.
    Giovanella L, Imperiali M, Piccardo A et al. (2018) Procalcitonin measurement to screen medullary thyroid carcinoma: a prospective evaluation in a series of 2705 patients with thyroid nodules. Eur J Clin Invest 48:e12934 CrossRefGoogle Scholar
  15. 15.
    Giovanella L (2012) Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. Exp Clin Endocrinol Diabetes 120:169–170 CrossRefGoogle Scholar
  16. 16.
    Plebani M, Fabbri LM (2015) Procalcitonin-guided antibiotic therapy: a potentially effective and efficient strategy. Clin Chem Lab Med 53:519–520 Google Scholar
  17. 17.
    Novotny AR, Luppa P, Rosenberg R et al. (2009) Procalcitonin can be used for monitoring sepsis in patients with medullary thyroid carcinoma. Thyroid 19:1287–1289 CrossRefGoogle Scholar

Copyright information

© Società Italiana di Patologia Clinica e Medicina di Laboratorio 2018

Authors and Affiliations

  1. 1.Medicina Nucleare e Centro TiroideIstituto Oncologico della Svizzera ItalianaBellinzonaSvizzera

Personalised recommendations